
    
      Primary Objective:

      To evaluate the percentage of complete molecular responses (CMR) after two cycles of
      remission induction therapy composed of two cycles of chemotherapy plus ponatinib. CMR is
      defined as BCR-ABL1 below the Limit of Quantification by Droplet Digital Polymerase Chain
      Reaction (ddPCR).

      Outline:

      Pre-phase:

      dexamethasone 10 mg/m2 PO (day -5 till -1), cyclophosphamide IV 200 mg/m2 (day -3 till -1),
      methotrexate 15 mg IT.

      Induction I:

      ponatinib 30 mg/day PO once daily (QD) continuously since day 1, rituximab 375 mg/m2 IV (day
      1), dexamethasone 10 mg/m2 PO (day 1-2, 8-11), vincristine 2 mg IV (day 1, 8, 15),
      Granulocyte-Colony Stimulating Factor (G-CSF) until recovery.

      Induction II:

      ponatinib 30 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 23), cyclophosphamide
      1000 mg/m2 IV (day 24), cytarabine 75 mg/m2 IV (day 26-29, 33-36), Granulocyte StimuG-CSF
      until recovery, methotrexate 15 mg IT (day 26, 33) methotrexate 15 mg + cytarabine 40 mg +
      dexamethasone 4 mg IT (day 40). Week 11: Primary endpoint assessment.

      Consolidation I (week 12):

      ponatinib 30 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), dexamethasone 10
      mg/m2 PO (day 1-4), vindesine 3 mg/m2 IV (day 2), methotrexate 1.5 g/m2 IV (day 2),
      cytarabine 2x 2 g/m2 IV (day 5), G-CSF until recovery, methotrexate 15 mg + cytarabine 40 mg
      + dexamethasone 4 mg IT (day 8). Patients in complete molecular response at week 11 will be
      treated with 5 additional blocks of chemotherapy followed by maintenance therapy; patients
      with molecular failure at week 11 will end the study and be directed to alloSCT.

      Consolidation II (week 18):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), cyclophosphamide 500
      mg/m2 IV (day 2,3), etoposide (VP-16) 75 mg/m2 IV (day 2,3), methotrexate 15 mg + cytarabine
      40 mg + dexamethasone 4 mg IT (day 1).

      Consolidation III+V (weeks 24 and 36):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), methotrexate 1.5 g/m2
      IV (day 2), vincristine 1 mg IV (day 2), 6-mercaptopurine 60 mg/m2 PO (day 2-8), methotrexate
      15 mg + cytarabine 40 mg + dexamethasone 4 mg IT at day 1.

      Consolidation IV+VI (weeks 30+40):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), dexamethasone 10
      mg/m2 PO (day 1-4), cytarabine 1.5 g/m2 IV (day 1+3+5), methotrexate 15 mg + cytarabine 40 mg
      + dexamethasone 4 mg IT (day 1). Maintenance: ponatinib 15 mg/day PO QD continuously 24
      months. (Doses of IV methotrexate and cytarabine are reduced in patients >55 years.)
    
  